CHMP recommends inotuzumab ozogamicin for adult ALL



B-cell precursor ALL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of inotuzumab ozogamicin (Besponsa®). The CHMP is recommending approval of inotuzumab ozogamicin for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL), including patients with Philadelphia chromosome-positive... [Read Article]

ALL, HL guidelines added to radiation therapy resource



Therapist preparing patient
to receive radiation
Photo by Rhoda Baer
The National Comprehensive Cancer Network® (NCCN) has added 9 disease sites to its NCCN Radiation Therapy Compendium™, a resource that provides a single access point for NCCN recommendations pertaining to radiation therapy (RT). The compendium provides guidance on all RT modalities recommended within... [Read Article]